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Abstract
Background: The ethanol extract of KOTMIN13, composed of Inula japonica Flowers, Trichosanthes kirilowii Semen,
Peucedanum praeruptorum Radix, and Allium macrostemon Bulbs, was investigated for its anti-asthmatic and
anti-allergic activities.
Methods: The anti-asthmatic effects of KOTMIN13 were evaluated on ovalbumin (OVA)-induced murine asthma
model. Anti-allergic properties of KOTMIN13 in bone-marrow derived mast cells (BMMC) and passive cutaneous
anaphylaxis (PCA) in vivo were also examined.
Results: In asthma model, KOTMIN13 effectively suppressed airway hyperresponsiveness induced by aerosolized
methacholine when compared to the levels of OVA-induced mice. KOTMIN13 treatment reduced the total
leukocytes, eosinophil percentage, and Th2 cytokines in the bronchoalveolar lavage fluids in OVA-induced mice.
The increased levels of eotaxin and Th2 cytokines in the lung as well as serum IgE were decreased by KOTMIN13.
The histological analysis shows that the increased inflammatory cell infiltration and mucus secretion were also
reduced. In addition, the degranulation and leukotriene C4 production were inhibited in BMMC with IC50 values of
3.9 μg/ml and 1.7 μg/ml, respectively. Furthermore, KOTMIN13 treatment attenuated mast-mediated PCA reaction.
Conclusions: These results demonstrate that KOTMIN13 has anti-asthmatic and anti-allergic effects in vivo and in
vitro models.
Keywords: Airway hyperresponsiveness (AHR), Bronchoalveolar lavage fluids (BALF), Bone-marrow derived mast
cells (BMMC), Passive cutaneous anaphylaxis (PCA), Degranulation, Leukotriene C4 (LTC4)
Background
The allergic reaction is biphasic. The immediate reaction
occurs within minutes caused by release of preformed
mediators from basophils and mast cells upon allergen
exposure. The late phase allergic reaction is caused by
mobilization and accumulations of inflammatory cells,
resulting further release of pharmacologically active media-
tors, sustaining the allergic response and promoting the late
allergic response [1]. Asthma is a chronic inflammatory
disorder of the airways associated with airway hyperrespon-
siveness (AHR) and airflow obstruction. Activation of Th2
cells in the airway is responsible for the pathogenesis of this
disease. Th2 cells orchestrate the recruitment and activa-
tion of mast cells and eosinophils through the release of
Th2 cytokines such as IL-4, IL-5 and IL-13, which are the
primary effector cells of the allergic response.
Mast cells are widely distributed throughout human
respiratory tract and found in alveoli walls [2]. They are
major effector cells that play a role in allergic inflamma-
tion. When activated through IgE-dependent or IgE-
independent ways, mast cells release preformed mediators
(histamine, proteases, and proteglycans) from their gran-
ules, lipid mediators (leukotrienes (LTs) and prostaglandins
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(PGs)) derived from arachidonic acid, and synthesize cyto-
kines and chemokines [2, 3].
The medicinal plants have been used in traditional
medicine to treat allergic diseases and their activities have
been demonstrated [4–6]. A Korean herbal medicine
named KOTMIN13, composed of Inula japonica Thun-
berg, Trichosanthes kirilowii Maximowicz var. japonica
kitamura, Peucedanum praeruptorum Dunn, and Allium
macrostemon Bge, has been used for the purpose of anti-
allergic and anti-asthmatic treatment in an oriental clinic,
but its activities have not been investigated. In the present
study, we investigated the effects of KOTMIN13 on the
treatment of asthma in vivo model as well as allergic
response by measuring inflammatory mediators in bone-
marrow derived mast cells (BMMC) and passive cutane-
ous anaphylaxis (PCA) in mice.
The results demonstrated that KOTMIN13 attenuated
ovalbumin (OVA)-induced airway inflammation by redu-
cing AHR, leukocyte infiltration, the levels of Th2 cytokine,
eotaxin, and serum IgE production, as well as mucus secre-
tion in a murine asthma model. Furthermore, we showed
that these effects were associated in part with the suppres-
sion of activated mast cells by inhibiting degranulation and
eicosanoid production in BMMC as well as PCA in vivo.
Methods
Plant materials
Herbs (Inula japonica Flowers, Trichosanthes kirilowii
Semen, Peucedanum praeruptorum Radix, and Allium
macrostemon Bulbs) were purchased from Humanherb
(Gyeongsan, Korea) and authenticated by Dr. H. Lee, an
herbalist. A voucher specimen has been deposited at the
National Development Institute of Korean Medicine. The
herbs were mixed according to the ratio of combination
(10:8:8:5), extracted with 30 % ethanol at a ratio of 1:10 (w/
v) and then refluxed for 24 h at 60 °C. The extracted solu-
tion was filtered and the solvent evaporated under vacuum
at 40 °C (Eyela, Tokyo, Japan), before being freeze-dried to
obtain a concentrated extract (15.4 % yield).
Murine asthmatic model and treatment
Six weeks old female BALB/c mice (16–20 g) were obtained
from Koateck (Seoul, Korea) and fed with laboratory chow
(Purina, Seoul, Korea) and water ad libitum. Animals were
acclimatized in a specific pathogen-free animal facility
under the conditions of 20–22 °C, 40–60 % relative humid-
ity, and 12 h/12 h (light/dark) cycle at least for 7 days. Mice
were sensitized by intraperitoneal administration on days 0
and 14 with 20 μg/ml of OVA in PBS mixed with equal vol-
umes of alum (1 mg) as an adjuvant. The mice were chal-
lenged from day 22 to 24 with 1 % OVA in PBS or PBS
using a nebulizer (NE-U17, OMRON, Tokyo, Japan). Mice
were randomly divided into 7 groups groups (n = 6 per
group): NC (negative control group, PBS sensitization and
challenge), OVA (OVA sensitization and challenge positive
group), KOTMIN13 (50, 100, 200 mg/kg), montelukast
(Mont, 20 mg/kg), and dexamethasone (Dex, 1 mg/kg).
KOTMIN13, Mont, or Dex was treated per orally 10 times
at every 12 h from 1 day before the first challenge to the
last challenge. Mice care and experimental procedures were
conducted with the approval of the animal care committee
of National Development Institute of Korean Medicine
(Approval No. KOTMIN-2015-001 for asthma).
AHR measurement
AHR to aerosolized methacholine (Sigma, St. Louis,
MO, USA) was measured in the plethysmograph cham-
ber (Emka Technologies, Paris, France) according to the
manufacture’s protocol. In brief, mice were stabilized in
the chamber for 10 min and then exposed to aerosolized
saline (1 min) as a control. Mice were then challenged
every 20 min with aerosolized methacholine. Increasing
doses of aerosolized methacholine were administered
and enhanced pause (Penh) was measured over the sub-
sequent 5 min as an index of airway obstruction.
Analysis of total cells and eosinophils in bronchoalveloar
lavage fluid (BALF)
BALF was obtained as described previously [7] and im-
mediately centrifuged (2 min, 4 °C, 160 g). After remov-
ing the supernatant, the cells were resuspended in
0.5 ml of PBS. After total cell counting, the suspended
cells were spun onto glass microscope slides (Shandon
Cytospin 4, Thermo Scientific, Kalamazoo, MI, USA)
and stained with hematoxylin and eosin (H&E). The
number of eosinophils was determined by counting at
least 100 cells in each of four different locations, and
data were expressed as a percentage of total leukocytes.
Enzyme-liked immunosorbent assays (ELISA)
The levels of eotaxin and cytokines in BALF and lung
homogenate supernatant were quantified using ELISA
according to the manufacturer’s instructions (R&D Sys-
tems, Inc., Minneapolis, MN, USA). Blood was collected
from mice via cardiac puncture and serum was obtained
by centrifugation (1000 g for 10 min at 4 °C) and stored at
−70 °C. Total serum IgE was measured by using Mouse
IgE ELISA kit (BD Biosciences, San Diego, CA, USA).
Histological analysis of lung tissue
The lungs were removed and fixed with 10 % (v/v) for-
maldehyde prior to embedding in paraffin. The sections
of fixed paraffin tissues were cut (4 μm thick), deparaffi-
nized and stained with H&E, and then periodic acid
Schiff reagent (PAS) to measure leukocyte accumulation
and mucus secretion, respectively.
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BMMC preparation
Bone marrow cells from male BALB/cJ mice were cultured
in RPMI 1640 media (2 mM L-glutamine, 100 U/ml peni-
cillin, 100 μg/ml streptomycin) and 10 % fetal calf serum
from (Hyclone, South Logan, UT, USA) containing 20 %
pokeweed mitogen-stimulated spleen condition medium
(Sigma). After 3 weeks, BMMC were used for assays.
Determination of β-hexosaminidase (hex) release, LTC4
generation and local anaphylaxis
The release of β-hex was quantified by spectrophotome-
tirc method as described previously [8]. For LTC4 deter-
mination, BMMC at a cell density of 1 × 106 cells/ml
were sensitized overnight with anti-dinitrophenyl (DNP)
IgE (500 ng/ml) and seeded in 96 well plate. After pre-
incubated with KOTMIN13 for 30 min, BMMC were
stimulated with DNP-human serum albumin (HSA,
100 ng/ml) for 15 min and all reactions were stopped by
centrifugation at 120 g at 4 °C for 5 min, and then the
supernatants were immediately used for LTC4 determin-
ation. The level of LTC4 was determined using EIA kit
(Cayman Chemical, Ann Arber, MI, USA) accordance
with the manufacturer’s protocols.
PCA test
The experimental method for PCA was described previ-
ously [8]. In short, mouse anti-DNP IgE (80 ng, Sigma)
were intradermally injected into ears of 7-week old ICR
male mice, followed 24 h later by oral administration of
KOTMIN13 (50, 100, and 200 mg/kg) or fexofenadine-
HCl (fexo), a histanime H1 receptor antagonist (Korea
Pharma, Seoul, 50 mg/kg). The mice were intravenously
challenged with DNP-HSA (60 μg, Sigma) in PBS contain-
ing 1 % (w/v) Evans blue and ears were removed to deter-
mine the amount of dye extravasation (at 630 nm). Mice
care and experimental procedures were performed under
the approval by Animal Care Committee of National
Development Institute of Korean Medicine (Approval No.
KOTMIN-2015-006 for PCA).
HPLC analysis
The chromatographic system was composed of a shi-
madzu LC-2AP Binary HPLC pump and a SPD-20A
Photodiode Array Detector (Shimadzu, Corp., Kyoto,
Japan). Detection and quantification were performed
using Empower software. The separation was carried out
on a Waters Sunfire C18 column (250 mm × 4.6 mm,
5 μm) at a column temperature of 40 °C. The injection
volume was 20 μL for a sample. The detection wave-
length was 330 nm. The mobile phase consisted of Solv-
ent A (0.3 % aqueous acetic acid (v/v)) and Solvent B
(acetonitrile) with gradient elution at the flow rate of
1.0 ml/min: 20 % Solvent B at 0 min, 40 % B at 40 min,
20 % B at 50 min, 20 % B at 60 min.
Statistical analysis
The data are expressed as mean ± SEM. Statistical signifi-
cance was determined by one-way ANOVA followed by
Duncan’s multiple range tests. A value of p < 0.05 was con-
sidered statistically significant.
Results
Effects of KOTMIN13 on AHR
AHR to methacholine (doses of 2.5, 5, 20, 30, 40 mg/kg)
was examined 18 h after the final OVA challenge. The
responsiveness of the control mice to methacholine was
weak as shown in Table 1. However, methacholine ad-
ministration significantly increased the Penh values in
OVA-induced and OVA-challenged mice compared with
the controls. KOTMIN13 treatment significantly re-
duced the Penh values in a dose dependent manner.
Treatment of mice with 200 mg/kg of KOTMIN13
strongly diminished the increased AHR and resulted in
similar dose–response curves of AHR to that of the Dex.
Effects of KOTMIN13 on total cells and eosinophils in BALF
To evaluate the anti-asthmatic effect of KOTMIN13 in
an in vivo model, the total number of leukocytes and the
percentage of eosinophils in the BALF were determined.
The total leukocytes in the BALF of the OVA-induced
Table 1 The effect of KOTMIN13 on AHR
Group Concentration Methacholine-induced Penh level
2.5 mg/kg 5 mg/kg 20 mg/kg 30 mg/kg 40 mg/kg
NC 1.56 ± 0.13 1.73 ± 0.03 2.15 ± 0.10 3.28 ± 0.25 3.65 ± 0.30
OVA 4.31 ± 0.26## 4.71 ± 0.20## 6.47 ± 0.36## 10.50 ± 1.00### 12.00 ± 0.57###
KOTMIN13 50 mg/kg 3.53 ± 0.13* 3.87 ± 0.25* 4.99 ± 0.42* 6.97 ± 0.37** 7.36 ± 0.88**
100 mg/kg 2.99 ± 0.23** 3.38 ± 0.18** 5.01 ± 0.28* 5.96 ± 0.39*** 6.98 ± 0.26***
200 mg/kg 2.34 ± 0.06*** 2.69 ± 0.23*** 3.70 ± 0.19*** 5.16 ± 0.18*** 5.17 ± 0.48***
Montelukast 20 mg/kg 3.03 ± 0.20** 3.43 ± 0.18** 5.34 ± 1.34* 5.92 ± 0.28*** 6.49 ± 0.23***
Dexamethasone 1 mg/kg 2.00 ± 0.05*** 2.30 ± 0.20*** 4.09 ± 0.12** 5.16 ± 0.29*** 5.13 ± 0.37***
Data were expressed as the mean ± SEM. ##P <0.01 and ###P <0.001 compared with the negative control (NC); *P <0.05, **P <0.01, and ***P <0.001 compared with
the OVA group
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lung tissues were increased as compared to control mice.
However, KOTMIN13 (100 and 200 mg/kg) inhibited the
OVA-induced recruitment of total leukocytes into the air-
way (Fig. 1a). The number of eosinophils in the BALF of
mice was determined as a percentage of the total number
of cells and KOTMIN13 treatment decreased the eosino-
phil percentage recruited into the airways of the OVA-
induced mice (Fig. 1b).
Effects of KOTMIN13 on eotaxin, cytokines, and serum IgE
The levels of Th2 cytokines and eotaxin were measured in
the BALF and lung homogenate supernatant using ELISA.
As shown in Fig. 2a, OVA sensitization and challenge in-
duced significant elevation of IL-4, IL-5, and IL-13 in the
BALF. KOTMIN13 treatment (at doses of 100 and 200 mg/
kg) decreased the concentration of these cytokines. The
levels of eotaxin and cytokines including eotaxin, IL-4, and
IL-5 in the lung of mice were also determined (Fig. 2b).
Eotaxin level was higher in OVA-induced mice than that in
control mice. KOTMIN13 treatment at dose of 100 and
200 mg/kg effectively inhibited the increased eotaxin in the
lung of OVA-induced mice. The levels of IL-4 and IL-5
were increased in the OVA-induced asthmatic mice when
compared to control mice and KOTMIN13 treatment
decreased the levels of IL-4 and IL-5 in the lung. Therefore,
KOTMIN13 treatment attenuated the eotaxin and Th2
cytokine levels in both BALF and the lung of OVA-induced
mice. We also determined whether KOTMIN13 modulated
the levels of serum IgE in OVA-induced mice. As shown in
Fig. 2c, the levels of serum IgE were significantly increased
in OVA-induced mice when compared to control mice.
However, KOTMIN13 treatment at 100 and 200 mg/kg led
to a decrease in the serum levels of IgE.
Histological analysis of lung tissue
To examine the inhibitory effects of KOTMIN13 on the
histological changes in the OVA-induced asthma model,
lung tissues were stained with H&E and PAS staining
solution. The infiltration of inflammatory cells into peri-
vascular and peribronchial areas was observed in OVA-
challenged mice. KOTMIIN13 treatment reduced the de-
gree of inflammatory cell infiltration in the perivascular
and peribronchial areas (Fig. 3a). Mucus secretion within
the bronchi of the lungs was also examined. An increase
in intensity of PAS staining was observed in the lung
tissues of OVA-induced mice and KOTMIN13 treatment
reduced mucus production in lung tissues when compared
with control (Fig. 3b). As expected, Dex significantly de-
creased perbronchial and perivascular lung inflammation.
Effect of KOTMIN13 on β-hex release, LTC4 generation,
and local anaphylaxis
Since histamine release by activated mast cells parallels the
release of β-hex, the effect of KOTMIN13 on degranulation
was determined by β-hex release. As shown in Fig. 4a,
KOTMIN13 treatment reduced the release of β-hex (IC50
= 3.9 μg/ml) in activated BMMC. The inhibitory activity of
KOTMIN13 on the LTC4 production was shown in a dose-
dependent manner with an IC50 value of 1.7 μg/ml (Fig. 4b).
These results suggested that KOTMIN13 has inhibitory ac-
tivities on the release of preformed and synthesized ecosa-
noid mediators in activated mast cells. We also examined
the anti-allergic activity of KOTMIN13 on PCA. An oral
administration of KOTMIN13 1 h before injection of anti-
gen inhibited the mast cell-mediated PCA reaction (31 % at
200 mg/kg and 32 % at 400 mg/kg), indicating that KOT-
MIN13 exerts anti-allergic effects through the inhibition of
mast cell degranulation.
HPLC analysis
More than 20 compounds from KOTMIN13 were purified
and identified. Among them, the identification of thirteen
compounds was based on the retention times and the UV
spectrum in comparison with authentic standards at a
Fig. 1 Effects of KOTMIN13 on the recruitment of leukocytes in BALF. BALF was obtained after aerosolized OVA inhalation challenge. a Total
leukocytes and eosinophils from the BALF were counted. b The eosinophils were expressed as a percentage of the total leukocytes. Values
represent mean ± SEM. #P < 0.05 and ###P < 0.001 compared with the negative control (NC); *P < 0.05, **P < 0.01, and ***P < 0.001 compared with
the OVA (OVA sensitized/challenged) group. Dex, dexamethasone
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Fig. 2 The effect of KOTMIN13 on the levels of eotaxin, cytokines, and serum IgE. The levels of Th2 cytokines (IL-4, IL-5, and IL-13) and eotaxin in (a)
BALF and (b) lung, and (c) serum IgE were determined using ELISA. Values represent mean ± SEM. #P < 0.05, ##P < 0.01, and ###P < 0.001 compared with
the negative control (NC); *P < 0.05, **P < 0.01, and ***P < 0.001 compared with the OVA (OVA sensitized/challenged) group. Dex, dexamethasone
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wavelength of 330 nm. The 13 compound profile of KOT-
MIN13 analyzed via HPLC (Fig. 5) showed that one phenyl
propanoid (secoisolariciresinol), four flavonoids (isoquerci-
trin, quercitrin, quercetin, and luteolin), four terpenes
(cucurbitacin, 1-O-acetylbritannilactone, britanin, and
tomentosin), two lignans (anthricin and pinoresinol), one
polyphenol (1,5-di-O-caffeoylquinic acid), and one couma-
rin (praeruptorin A) were isolated and purified from
Fig. 3 Histological analysis of lung tissue. Histological analysis of lung tissue was conducted. Lung sections of control mice and asthmatic mice
treated with KOTMIN13 or Dex were stained with (a) H&E or (b) PAS. Arrows indicates inflammatory cells and mucus production. Values represent
mean ± SEM. NC, negative control; OVA, OVA sensitized/challenged; K, KOTMIN13; Dex, dexamethasone. Magnification 200×
Lee et al. BMC Complementary and Alternative Medicine  (2016) 16:169 Page 6 of 10
KOTMIN13. The chemical structures were determined by
comparison of their NMR spectral data with standards.
Discussion
Asthma is a chronic inflammatory disorder of airway in
which many cells and cellular components play a role, in
particular, mast cells, eosinophils, T cells, neutrophils, and
epithelial cells [9]. Although corticosteroids with potent
anti-inflammatory and anti-allergy activities remain the
major therapy for allergic diseases, long-term medication
can lead to serious side effects and complications [10]. Vari-
ous plant extracts have been used in traditional medicine to
treat allergic diseases and their activities have been demon-
strated [4–6]. Therefore, many researchers in Asia have tried
to generate data to support herbal medicine for usage as
natural anti-inflammatory products because it is necessary
to demonstrate that herbal medicine is safe and effective.
KOTMIN13 is composed of four herbs: Inula japonica
Flowers, Trichosanthes kirilowii Semen, Peucedanum
praeruptorum Radix, and Allium macrostemon Bulbs. It
is modified from Guaruhaebaebaekju-tang, which has
frequently used for asthma treatment in traditional
herbal medicine. Although KOTMIN13 has been used
for treatment of anti-inflammatory and anti-allergic dis-
eases such as asthma and allergic rhinitis in a local
clinic, there are still no valid data of its anti-allergic
effect and the mechanism underlying the anti-asthmatic
effect of KOTMIN13. In previous study, we demon-
strated that KOTMIN13 inhibits the production of
inflammatory mediators including NO, PGE2, and pro-
inflammatory cytokines that are mediated through NF-
kB and MAPK activity inhibition in LPS-induced RAW
264.7 cells. In addition, KOTMIN13 ameliorated the de-
velopment of phorbol ester 12-O-tetradecanoylphorbol-
13-acetate-induced ear edema and carrageenan-induced
paw edemas in acute inflammatory edema models (un-
published data).
Since various mediators released during allergic inflam-
mation play a critical role in AHR development [11], AHR
is a hallmark of clinical symptom for asthma. Increased
Th2 cytokines such as IL-4, IL-5, and IL-13 play a vital
role in asthmatic responses. IL-4 increases IgE production
Fig. 4 Effect of KOTMIN13 on β-hex release, LTC4 production, and PCA. BMMC were sensitized with anti-DNP IgE, treated with KOTMIN13, and then
challenged with DNP-HSA. a β-hex and b LTC4 released into the supernatant were determined. c In PCA test, mice were sensitized by intradermal injection
of IgE (80 ng) into mouse ears and intravenously challenged with DNP-HSA (60 μg) containing Evans blue after oral administration of KOTMIN13 for 1 h.
Ears were removed for measuring the amount of dye extravasation. Values represent mean ± SEM. ##P< 0.01 compared with the negative control
(NC, anti-DNP IgE); *P< 0.05, **P< 0.01, and ***P< 0.001 compared with the positive control (PC, anti-DNP IgE/DNP-HSA)
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and participates in the initiation of Th2 inflammatory re-
sponses. IL-5 plays a crucial role in AHR by mobilizing
and activating eosinophils [12]. IL-13 has been shown to
induce mucus hypersecretion and AHR in murine asthma
models in which cysteinyl-LTs might be causative agents
of AHR [13]. In the present study, our results demon-
strated that KOTMIN13 treatment alleviated AHR, de-
creased total leukocyte recruitment, and the production of
Th2 cytokines in the BALF and lungs of OVA-induced
mice, which was consistent with the results of the histo-
logical analysis. Therefore, the reduced Th2 cytokine pro-
duction in this experiment led to low levels of serum IgE
as well as decreased leukocyte infiltration and mucus se-
cretion into the lung tissue of asthmatic mice.
Histamine is one of the most potent mediators in the
acute phase of immediate hypersensitivity and triggers
acute symptoms due to its rapid effects on the bronchial
and smooth muscle cells [14]. Cysteinyl LTs also affect
inflammatory cell recruitment, mucus production, air-
ways remodeling, and pulmonary vascular leakage [15].
In this study, the effect of KOTMIN13 on β-hex release
from stimulated BMMC was determined and revealed
that KOTMIN13 inhibited β-hex release in a dose
dependent manner. In addition, LTC4 production from
stimulated BMMC was also reduced by KOTMIN13
treatment. These results indicate that KOTMIN13 sup-
presses the degranulation and LTC4 production which
attenuate inflammatory response with asthma and other
inflammatory disease. PCA is one of the most important
in vivo models of immediate hypersensitivity in local al-
lergic reaction. In this study, PCA reaction was induced
by the injection of IgE and antigen and oral administra-
tion of KOTMIN13 decreased the PCA reaction in a
dose dependent manner, indicating its role in the
prevention or treatment of mast cell-mediated allergic
reactions such as asthma.
Among thirteen compounds isolated from KOT-
MIN13, sesquiterpene lactons such as 1-O-acetylbritan-
nilactone, britanin, and tomentosin from Inulae flos
have been proven to exhibit anti-inflammatory activities
in others and our previous studies [16–19]. Flavonols
(quercetin, quercitrin, and isoquercetin) from Inulae flos
function as anti-inflammatory and anti-allergic activities
[20–25]. Luteolin also attenuates AHR in OVA-induced
mice and inhibited mast cell-mediated allergic
inflammation [26, 27]. Other compounds from Inulae
flos such as 1,5-di-O-dicaffeoylquinic acid were identi-
fied in HPLC analysis. Recently, several other anti-
inflammatory compounds from Inulae flos were also iso-
lated [28, 29]. Praeurptorin A isolated from Peucedanum
praeruptorum Radix and Allium macrostemon Bulbs has
showed anti-inflammatory effects in LPS-stimulated
RAW 264.7 cells, as well as suppressed OVA-induced
airway inflammation and remodeling in mice [30–32].
Two compounds, cucurbitacin and pinoresinol from
Trichosanthes kirilowii semen were identified by HPLC
analysis. Cucurbitacin B has anti-inflammatory activities
in vitro and in vivo and pinoresinol attenuates inflam-
matory responses of microglia on the production of
inflammatory mediators by the inhibition of ERK and
NF-kB activities [33–35]. Although compounds such as
praeurptorin B, praeurptorin C, 3,4-dihydroxy benzoic
acid, di-O-caffeoylquinic acid, and miquelianin were not
in the HPLC chromatogram, they were isolated from
KOTMIN13. The active compounds mentioned above
are involved in the anti-allergic responses of KOT-
MIN13, and other compounds derived from KOTMIN13
may have anti-allergic activity as well.
Fig. 5 Representative HPLC-UV chromatograms of KOTMIN13 extract and its components. 1, (−)Secoisolariciresinol; 2, Isoquercitrin; 3, Cucurbitacin;
4, Anthricin; 5, 1,5-di-O-caffeoylquinic acid; 6, Quercitrin; 7, Quercetin; 8, Luteolin; 9, Praeruptorin A; 10, 1-O-acetylbritannilactone; 11, Britanin; 12,
(−)Pinoresinol; 13, Tomentosin
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Conclusion
In summary, our study suggests that KOTMIN13 is an
alternative natural drug in the OVA-induced airway inflam-
mation by decreasing AHR, leukocyte infiltration, Th2 cyto-
kines, and IgE production, as well as mucus secretion in a
mouse model of asthma. In addition, anti-allergic activities
of KOTMIN13 could be in part mediated by decreasing
pharmacologically active mediators from mast cells.
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